Stock Scorer

Quantum BioPharma Ltd. (QNTM)

Every figure this model derived for QNTM, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2024-12-31
cash 1,905,357 CashAndCashEquivalents 2025-12-31
current assets 6,478,353 CurrentAssets 2025-12-31
current liabilities 6,058,294 CurrentLiabilities 2025-12-31
equity 6,924,475 EquityAttributableToOwnersOfParent 2025-12-31
interest expense 158,063 FinanceCosts 2025-12-31
ocf -8,237,012 CashFlowsFromUsedInOperatingActivities 2025-12-31
sbc 2,945,502 ExpenseFromSharebasedPaymentTransactionsWithEmployees 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up QNTM on one particular measure came for.

RatioValue
current ratio1.07
current ratio reported1.07
dilution pct86.43
ev owner earnings-2.08
interest cover-96.81
roic-191.29

Everything else this filing tags

308 more elements from QNTM's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.

ElementNewestAs of PeriodsUnit
RetainedEarnings-198,286,1702025-12-31 26USD
IssuedCapital150,470,3252024-12-31 12USD
NetDeferredTaxAssets117,523,6702025-12-31 18USD
IssuedCapital98,016,6492019-12-31 4CAD
RetainedEarnings-78,518,0052019-12-31 4CAD
Assets57,447,4632019-12-31 4CAD
EquityAndLiabilities57,447,4632019-12-31 4CAD
ComprehensiveIncome-52,125,8762019-12-31 4CAD
AccountingProfit-52,013,1862019-12-31 4CAD
ProfitLoss-52,013,1862019-12-31 4CAD
Equity48,222,0872019-12-31 6CAD
WeightedAverageShares38,732,3812022-12-31 3shares
ProfitLossFromOperatingActivities-36,669,9962019-12-31 4CAD
SharePremium35,405,8122025-12-31 26USD
ExpenseByNature34,262,9962019-12-31 4CAD
DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised32,754,2532019-12-31 4CAD
ExpenseByNature27,429,6112022-12-31 8USD
ComprehensiveIncome-26,956,8402025-12-31 28USD
ProfitLossFromContinuingOperations-26,956,8402025-12-31 30USD
ProfitLossAttributableToNoncontrollingInterests-26,956,8402025-12-31 30USD
OtherComprehensiveIncome-26,916,1022025-12-31 26USD
ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects-26,175,2862025-12-31 26USD
ProfitLoss-23,253,8082025-09-30 24USD
SharePremium23,091,0992019-12-31 4CAD
IntangibleAssetsOtherThanGoodwill22,358,9322019-12-31 4CAD
CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners17,850,1742022-12-31 7USD
KeyManagementPersonnelCompensation17,312,5772019-12-31 4CAD
ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations16,400,0002022-12-31 2CAD
AdjustmentsForSharebasedPayments16,061,3192019-12-31 4CAD
IncreaseDecreaseThroughSharebasedPaymentTransactions16,061,3192019-12-31 4CAD
ProfitLossFromOperatingActivities-15,302,3742025-12-31 25USD
OperatingExpense15,302,3742025-12-31 30USD
AccountingProfit-14,915,5292024-12-31 15USD
GeneralAndAdministrativeExpense14,811,5292019-12-31 4CAD
TaxExpenseIncomeAtApplicableTaxRate-13,783,4942019-12-31 4CAD
IncreaseDecreaseInCashAndCashEquivalents-13,202,1932019-12-31 4CAD
ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations12,730,9422022-12-31 1USD
KeyManagementPersonnelCompensationSharebasedPayment12,476,3852019-12-31 4CAD
GainsLossesOnChangeInFairValueOfDerivatives-11,909,5322025-12-31 38USD
PropertyPlantAndEquipment11,804,1452019-12-31 4CAD
NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod11,780,8642019-12-31 4CAD
AdjustmentsForFairValueGainsLosses11,669,1572019-12-31 4CAD
CashFlowsFromUsedInFinancingActivitiesContinuingOperations11,618,8702024-12-31 17USD
IssueOfEquity11,539,4172019-12-31 4CAD
Assets11,160,9092025-12-31 26USD
EquityAndLiabilities11,160,9092025-12-31 26USD
LeasesAsLesseeRelatedPartyTransactions9,612,4092024-09-30 3USD
GeneralAndAdministrativeExpense9,410,0972024-12-31 25USD
Liabilities9,225,3762019-12-31 4CAD
SellingGeneralAndAdministrativeExpense9,047,9182025-12-31 13USD
ProfitLossAttributableToOwnersOfParent-8,842,4612024-09-30 4USD
PurchaseOfInvestmentProperty7,999,9912018-12-31 2CAD
TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss7,797,2902019-12-31 4CAD
NoncurrentTradeReceivables7,431,6562022-12-31 2USD
IncreaseDecreaseThroughAcquisitionOfSubsidiary7,290,7312021-12-31 2USD
AcquisitiondateFairValueOfTotalConsiderationTransferred7,290,7312023-12-31 1USD
TaxExpenseIncomeAtApplicableTaxRate-7,143,5602025-12-31 18USD
CashFlowsFromUsedInOperatingActivitiesContinuingOperations-6,876,4792024-12-31 17USD
ShareIssueRelatedCost6,634,4052018-12-31 2CAD
IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate6,186,2512023-12-31 1USD
CashFlowsFromUsedInFinancingActivities6,098,9662025-12-31 30USD
Liabilities6,058,2942025-12-31 26USD
PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod6,000,0002019-12-31 2CAD
CashFlowsFromUsedInFinancingActivities5,332,4542019-12-31 4CAD
ChangesInIntangibleAssetsOtherThanGoodwill5,145,9322024-06-30 5USD
Equity5,102,6152025-12-31 46USD
KeyManagementPersonnelCompensationShorttermEmployeeBenefits4,836,1922019-12-31 4CAD
ProceedsFromIssuingShares4,593,7772019-12-31 4CAD
IntangibleAssetsOtherThanGoodwill4,513,2072025-12-31 25USD
TradeAndOtherCurrentPayables4,467,8262019-12-31 4CAD
TradeAndOtherPayables4,362,0682024-12-31 10USD
AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables4,270,3972024-12-31 21USD
GainsOnDisposalsOfPropertyPlantAndEquipment4,249,5822022-12-31 1USD
TradeAndOtherCurrentPayables4,182,0832025-12-31 26USD
IncreaseDecreaseInCashAndCashEquivalents-4,090,5152025-12-31 15USD
AmortisationIntangibleAssetsOtherThanGoodwill3,894,4672020-12-31 2USD
ProfessionalFeesExpense3,730,5562019-12-31 4CAD
AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives-3,568,3052019-12-31 2CAD
LossesOnChangeInFairValueOfDerivatives3,568,3052019-12-31 2CAD
KeyManagementPersonnelCompensation3,495,9382025-12-31 38USD
ProfessionalFeesExpense3,278,7352025-12-31 38USD
ProceedsFromIssueOfBondsNotesAndDebentures3,243,1652025-12-31 9USD
AdjustmentsForDepreciationAndAmortisationExpense3,146,6802019-12-31 4CAD
DepreciationAndAmortisationExpense3,146,6802019-12-31 4CAD
AdjustmentsForSharebasedPayments2,945,5022025-12-31 20USD
IncreaseDecreaseThroughSharebasedPaymentTransactions2,945,5022025-12-31 20USD
ResearchAndDevelopmentExpense2,763,1742025-12-31 37USD
CurrentDerivativeFinancialLiabilities2,646,2692019-12-31 2CAD
ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities2,500,4252025-12-31 3USD
AdjustmentsForProvisions-2,477,5592025-03-31 15USD
IssueOfConvertibleInstruments2,420,0002025-03-28 16CAD
GrossProfit-2,407,0002019-12-31 2CAD
LossesOnLitigationSettlements2,350,0002025-12-31 5USD
WagesAndSalaries2,267,3082019-12-31 4CAD
WagesAndSalaries2,204,3192025-12-31 38USD
AccrualsClassifiedAsCurrent2,200,2322025-12-31 22USD
AdministrativeExpense2,172,8242019-12-31 4CAD
ProceedsFromBorrowingsClassifiedAsFinancingActivities2,113,3862025-12-31 13USD
TradeAndOtherCurrentReceivables2,070,0552019-12-31 4CAD
TradeAndOtherReceivables2,070,0552019-12-31 4CAD
IssueOfConvertibleInstruments2,000,0002025-12-31 21USD
KeyManagementPersonnelCompensationSharebasedPayment1,994,5582025-12-31 38USD
TradeAndOtherCurrentPayablesToTradeSuppliers1,981,8512025-12-31 22USD
CostOfSales1,959,1112019-12-31 2CAD
CashFlowsFromUsedInInvestingActivities-1,952,4692025-12-31 30USD
OtherIncome1,946,4912025-12-31 24USD
CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued1,908,4122019-12-31 2CAD
NoncontrollingInterests-1,821,8602025-12-31 21USD
GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss-1,692,8422024-12-31 19USD
CashFlowsFromUsedInInvestingActivitiesContinuingOperations-1,503,5592024-12-31 17USD
KeyManagementPersonnelCompensationShorttermEmployeeBenefits1,501,3802025-12-31 38USD
AdjustmentsForFinanceIncome-1,491,0012025-12-31 25USD
IncreaseDecreaseThroughExerciseOfWarrantsEquity1,372,7632023-12-31 3USD
OtherExpenseByNature1,330,0432023-09-30 2USD
InventoryWritedown20111,315,9412019-12-31 2CAD
Borrowings1,300,5492025-12-31 8USD
AdditionsFromPurchasesBiologicalAssets1,297,7342019-12-31 2CAD
DeferredTaxAssets1,242,0402025-12-31 1USD
DeferredTaxLiabilities1,242,0402025-12-31 1USD
ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod1,181,4992025-12-31 19USD
AdjustmentsForIncreaseDecreaseInTradeAccountPayable1,178,4972025-12-31 9USD
AdjustedWeightedAverageShares1,136,9222024-12-31 29shares
AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables-1,079,0672019-12-31 4CAD
IssuedCapitalOrdinaryShares1,028,7802025-09-30 8USD
NumberOfSharesIssued1,000,0002023-12-31 1shares
AdjustmentsForDecreaseIncreaseInInventories-942,9392019-12-31 2CAD
Inventories942,9392019-12-31 2CAD
AdjustmentsForUnrealisedForeignExchangeLossesGains934,1002022-12-31 7USD
RepairsAndMaintenanceExpense924,9452019-12-31 4CAD
AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables825,1202019-12-31 4CAD
RepaymentsOfCurrentBorrowings800,0002025-12-31 3CAD
ComprehensiveIncomeAttributableToNoncontrollingInterests-781,5542025-12-31 26USD
CashAndCashEquivalentsRecognisedAsOfAcquisitionDate768,9642023-12-31 1USD
IncreaseDecreaseThroughExerciseOfOptions732,5982019-12-31 4CAD
ProceedsFromExerciseOfOptions732,5982019-12-31 4CAD
AdjustmentsForDecreaseIncreaseInBiologicalAssets-682,7392019-12-31 2CAD
AdjustmentsForGainsLossesOnChangeInFairValueLessCostsToSellBiologicalAssets-682,7392019-12-31 2CAD
GainsLossesOnFairValueAdjustmentAttributableToPhysicalChangesBiologicalAssets682,7392019-12-31 2CAD
IncreaseDecreaseThroughTransfersAndOtherChangesBiologicalAssets682,7392019-12-31 2CAD
OtherPayables619,0292024-12-31 10USD
SellingExpense616,0022022-12-31 1USD
DecreaseDueToHarvestBiologicalAssets614,9952019-12-31 2CAD
ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod614,5202019-12-31 2CAD
AdjustmentsForDepreciationAndAmortisationExpense545,7802025-12-31 28USD
DepreciationAndAmortisationExpense545,7802025-12-31 38USD
AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives521,8092022-12-31 8USD
InterestIncomeOnLoansAndReceivables513,9252024-12-31 4USD
CurrentDebtInstrumentsIssued472,4972025-12-31 8USD
PurchaseOfInvestmentProperty462,3252025-12-31 26USD
PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod462,3252025-12-31 13USD
ProceedsFromSalesOfInvestmentProperty460,5082025-12-31 20USD
CurrentInvestments459,0802025-12-31 22USD
InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod459,0802025-12-31 28USD
LongtermDeposits459,0802025-12-31 5USD
CurrentPrepaidExpenses430,3812019-12-31 4CAD
PaymentsForDebtIssueCosts400,0002024-12-31 3CAD
RevenueFromInterest397,9392024-09-30 5USD
IssueOfEquity391,3832025-12-31 16USD
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities389,6402019-12-31 2CAD
TradeAndOtherCurrentReceivables374,3772022-12-31 8USD
GainsLossesOnExchangeDifferencesOnTranslationNetOfTax-366,5462024-12-31 17USD
ProceedsFromIssuingShares338,3312025-12-31 30USD
GrossLoanCommitments315,5282018-12-31 2CAD
CashFlowsFromUsedInInvestingActivities-306,9092019-12-31 4CAD
CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued300,5492022-12-31 7USD
FeeAndCommissionExpense288,3732024-09-30 2USD
GainsOnDisposalsOfInvestments285,3142025-12-31 2USD
DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares258,5882025-12-31 34shares
Revenue257,0992019-12-31 2CAD
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss243,4682019-12-31 2CAD
InterestRevenueExpense236,0842025-12-31 33USD
AdjustmentsForFairValueGainsLosses234,2262022-12-31 8USD
OtherReceivables231,0532025-12-31 25USD
TradeAndOtherReceivables231,0532025-12-31 25USD
LeaseLiabilities215,8742022-12-31 10USD
WarrantLiability212,0022024-12-31 10USD
AdjustmentsForInterestExpense206,4542019-12-31 2CAD
DirectorsRemunerationExpense203,5212019-12-31 4CAD
LeaseLiabilities202,8692019-12-31 4CAD
AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables196,6772025-12-31 30USD
NetForeignExchangeLoss186,9592020-12-31 2USD
ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment175,8242019-12-31 2CAD
AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets-175,1942025-12-31 3USD
GainsLossesOnDisposalsOfInvestments175,1942025-12-31 3USD
CurrentAssetsRecognisedAsOfAcquisitionDate167,7762023-12-31 1USD
NumberOfOutstandingShareOptions160,9562025-12-31 16pure
NumberOfShareOptionsExercisableInSharebasedPaymentArrangement160,9562025-12-31 9pure
NumberOfShareOptionsGrantedInSharebasedPaymentArrangement155,6922025-12-31 9pure
ProceedsFromExerciseOfOptions148,0862025-12-31 21USD
NoncurrentLeaseLiabilities146,6622019-12-31 2CAD
CashOutflowForLeases143,0712022-12-31 7USD
DepreciationBiologicalAssets131,9552019-12-31 2CAD
RightofuseAssets127,4102019-12-31 6CAD
OtherIncome125,5362019-12-31 4CAD
LossesOnChangeInFairValueOfDerivatives117,1362025-12-31 20USD
DepreciationRightofuseAssets114,9072022-12-31 6USD
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities113,8622025-12-31 30USD
OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation-112,6902019-12-31 2CAD
ReserveOfExchangeDifferencesOnTranslation-112,6902019-12-31 2CAD
TradeAndOtherPayablesRecognisedAsOfAcquisitionDate103,8242023-12-31 1USD
CurrentLeaseLiabilities103,1652025-12-31 26USD
ValueAddedTaxReceivables102,7142025-12-31 12USD
ExercisePriceShareOptionsGranted2019102,5632024-06-30 2USD/shares
RightofuseAssets102,3202025-12-31 28USD
AdditionsToRightofuseAssets98,6482022-12-31 3USD
IncreaseDecreaseThroughExerciseOfWarrantsEquity94,9912019-12-31 4CAD
ReserveOfExchangeDifferencesOnTranslation91,5332025-12-31 25USD
AdjustmentsForDecreaseIncreaseInOtherCurrentAssets86,3772024-12-31 13USD
GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss84,5682019-12-31 4CAD
IssuedCapitalPreferenceShares84,3582025-12-31 4USD
InterestReceivable73,5752025-12-31 18USD
TradeReceivables70,4782024-09-30 2USD
PropertyPlantAndEquipment67,0292025-12-31 24USD
AdjustmentsForInterestExpense65,7342025-12-31 16USD
AdjustmentsForDecreaseIncreaseInInventories65,1092025-12-31 9USD
NetForeignExchangeGain62,3852020-12-31 2USD
CashOutflowForLeases56,2072019-12-31 2CAD
CurrentLeaseLiabilities56,2072019-12-31 2CAD
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities56,2072019-12-31 2CAD
RawMaterials55,5682025-09-30 3USD
AdjustmentsForDecreaseIncreaseInPrepaidExpenses53,7462025-12-31 9USD
Inventories52,1332025-12-31 15USD
DepreciationRightofuseAssets48,7642019-12-31 2CAD
ProceedsFromExerciseOfWarrants43,2572025-12-31 10USD
ProceedsFromIssuingOtherEquityInstruments43,2572025-12-31 3USD
NumberOfInstrumentsOtherEquityInstrumentsGranted41,0362024-12-31 9pure
OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation40,7382025-12-31 21USD
NumberOfShareOptionsExercisedInSharebasedPaymentArrangement37,1922025-12-31 7pure
NumberOfShareOptionsExercisedInSharebasedPaymentArrangement37,1922025-12-31 6options
RawMaterialsAndConsumablesUsed33,8272025-12-31 5USD
PaymentsForShareIssueCosts32,7052019-12-31 4CAD
NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement32,6902024-12-31 11pure
DirectorsRemunerationExpense29,5872025-03-31 3USD
OtherReceivables23,5302019-12-31 4CAD
FinishedGoods22,0542025-09-30 3USD
InterestExpenseOnLeaseLiabilities19,0622022-12-31 7USD
ChangesInInventoriesOfFinishedGoodsAndWorkInProgress18,3062025-12-31 5USD
CurrentPrepaidExpenses15,2902025-12-31 26USD
InterestExpenseOnLeaseLiabilities15,2582019-12-31 2CAD
NumberOfShareOptionsExpiredInSharebasedPaymentArrangement12,5002025-03-31 6pure
WarrantReserve10,0092025-12-31 18USD
InterestExpense9,3432024-12-31 14USD
DividendsPaidToNoncontrollingInterests8,6732023-12-31 3USD
GainsOnLitigationSettlements5,1562024-09-30 2USD
OtherCurrentReceivables4,8742024-09-30 2USD
NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement1,9002023-12-31 1pure
ForeignExchangeLoss-1,0392025-12-31 12USD
WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement20193532024-09-30 2CAD/shares
WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement20191362023-12-31 1USD/shares
WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019192025-12-31 9USD/shares
WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019192025-09-30 8CAD/shares
WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019192025-12-31 5USD/shares
WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019192025-09-30 4CAD/shares
WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019192025-12-31 5USD/shares
WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019192025-09-30 4CAD/shares
BasicEarningsLossPerShareFromContinuingOperations-82025-12-31 19USD/shares
DilutedEarningsLossPerShareFromContinuingOperations-82025-12-31 16USD/shares
BasicAndDilutedEarningsLossPerShare-72019-12-31 4CAD/shares
WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement201962025-09-30 4CAD/shares
WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement201962025-12-31 2USD/shares
WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement201952025-03-31 4USD/shares
ParValuePerShare42024-09-06 5USD/shares
BasicAndDilutedEarningsLossPerShareFromContinuingOperations-22020-12-31 2USD/shares
ProportionOfVotingPowerHeldInSubsidiary12025-12-31 2pure
ParValuePerShare02025-07-21 3CAD/shares
PercentageOfVotingEquityInterestsAcquired02023-07-31 7pure
BasicAndDilutedEarningsLossPerShareFromDiscontinuedOperations-02020-12-31 2USD/shares
ApplicableTaxRate02025-12-31 22pure
ProportionOfOwnershipInterestsHeldByNoncontrollingInterests02025-12-31 14pure
ProportionOfVotingPowerHeldInAssociate02025-12-31 2pure
DilutedEarningsLossPerShareFromDiscontinuedOperations02022-12-31 3USD/shares
BorrowingsInterestRate02023-12-31 5pure
GainsLossesOnFairValueAdjustmentInvestmentProperty02025-11-30 1USD
GainsLossesOnFairValueAdjustmentInvestmentProperty02025-11-30 1CAD
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss02022-12-31 8USD
BiologicalAssets02019-12-31 4CAD
CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations02022-12-31 8USD
CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations02024-12-31 17USD
CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations02024-12-31 17USD
CurrentBiologicalAssets02019-12-31 4CAD
CurrentDerivativeFinancialLiabilities02025-12-31 11USD
DeferredTaxExpenseIncome02019-12-31 4CAD
DeferredTaxExpenseIncome02023-12-31 9USD
IncreaseDecreaseThroughExerciseOfOptions02024-12-31 15USD
NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners02022-12-31 6USD
NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod02025-12-31 21USD
NoncurrentLeaseLiabilities02023-12-31 10USD
ProfitLossFromDiscontinuedOperations02024-12-31 17USD
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities02024-12-31 16USD
RepaymentsOfBondsNotesAndDebentures02023-12-31 11USD
ShareIssueRelatedCost02025-12-31 14USD
TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss02025-12-31 18USD
TaxEffectOfForeignTaxRates02025-12-31 18USD
BasicEarningsLossPerShareFromDiscontinuedOperations02024-12-31 15USD/shares
OtherCurrentPayables02022-12-31 4USD
AllowanceAccountForCreditLossesOfFinancialAssets02024-12-31 6USD
NetInvestmentInFinanceLease02023-12-31 4USD
TaxEffectFromChangeInTaxRate02025-12-31 14USD
AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination02023-12-31 3USD
ConsiderationPaidReceived02025-12-31 16USD
CurrentFinanceLeaseReceivables02025-12-31 18USD
GainsLossesOnFinancialLiabilitiesAtFairValueThroughProfitOrLoss02024-12-31 17USD
ImpairmentLoss02025-12-31 20USD
NoncurrentFinanceLeaseReceivables02025-12-31 14USD
CurrentDeferredIncomeOtherThanCurrentContractLiabilities02025-12-31 8USD
CurrentWarrantLiability02025-12-31 8USD
LoansAndAdvancesAtAmortisedCostAllowanceForExpectedCreditLosses02025-12-31 2USD
NetDeferredTaxLiabilities02025-12-31 1USD

What to be careful about

What this model itself distrusts about QNTM's figures. Written by the derivation as it ran, not added afterwards.